(A) Effect of FIP200 deficiency on peritoneal ovarian cancer progression. WT (Fip200+/+) and FIP200-deficient (Fip200–/–) mice were (I.P.) injected with ID8 tumor cells. Tumor growth was monitored (n = 6 to 8 mice/group, mean ± SEM). *P < 0.05, **P < 0.01 (Mann-Whitney U test) between Fip200+/+ and Fip200–/– tumor-bearing mice. (B) Percentage of T cells in total immune cells between Fip200+/+ and Fip200–/– tumor-bearing mice (n = 11 mice/group, mean ± SEM). *P < 0.05 (Mann-Whitney U test). (C) Percentage of Ki67+ T cells between Fip200+/+ and Fip200–/– tumor-bearing mice (n = 4 mice/group, mean ± SEM). *P < 0.05 (Mann-Whitney U test). (D and E) Percentage of IFN-γ+ (D) and TNF-α+ (E) T cell subsets in Fip200+/+ and Fip200–/– tumor-bearing mice (n = 5 mice/group, mean ± SEM). **P < 0.01 (Mann-Whitney U test) in both CD4+ and CD8+ T cells.